123 results about "Cirrhotic liver" patented technology

The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,

The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.

The invention provides a group of biomarkers which can be used for detecting liver fibrosis and cirrhosis. The biomarkers refer to metabolite components existing in a biological sample of a subject body and comprise a plurality of metabolites, wherein the metabolites are selected from cholic acid, amino acid and fatty acid. Metabolite combination comprises at least one amino acid, fatty acid and cholic acid, the metabolite combination is differentially expressed in at least one target plasma or serum and in a control plasma or serum. The biomarkers can optionally be combined with clinical indicators for diagnosis of liver fibrosis in the subject body. The biomarker composition has the characteristics of high sensitivity and specificity for pathological staging diagnosis of liver fibrosis patients, and can be clinically applied as a non-invasive means to improve clinical diagnosis and reduce puncture pain of the patients. The invention further provides a use method of the biomarkers andkits containing the biomarkers.

The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine/threonine kinases and for the treatment of malignant or benign tumours and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1/DR4 and TRAIL-R2/DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1/DR4 and/or TRAIL-R2/DR5 agonists.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1/DR4 and TRAIL-R2/DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1/DR4 and/or TRAIL-R2/DR5 agonists.

The invention belongs to the field of marine drugs, and in particular relates to an application of oligoguluronates in preparation of drugs for prevention and treatment of liver damage and various hepatitis, liver fibrosis or cirrhosis. The oligoguluronates are used in preparation of the drugs for protection of livers and treatment of various hepatitis, liver fibrosis or cirrhosis; the oligoguluronates adopt algin as a raw material, and oligoguluronic acids with different molecular weights are obtained through a chemical degradation method or a physical degradation or a combination of the two degradation methods; the oligoguluronic acids are neutralized to prepare lithium salts, sodium salts, potassium salts, calcium salts or magnesium salts of the oligoguluronic acids with different molecular weights, wherein a molecular skeleton is a linear oligosaccharide compound formed by connecting L-guluronic acid (G) through alpha-(1,4)-glycosidic bonds. The products are derived from the marine natural product, have many advantages of abundant resources, easy industrialization, safety, effectivity and the like, and have broad development and application prospects in prevention and treatment of liver damage and various hepatitis, liver fibrosis or cirrhosis.

The invention relates to the technical field of medicines. Chalcone is a natural component in plants and has antibiotic and antifungal effects, and derivatives of the chalcone also have the effect of resisting tumors and the like. At present, no document is reported that the derivatives of the chalcone have the effect of reducing activity of blood fat and protecting the liver. The invention provides derivatives of the dihydrochalcone having a general formula I. Through tests of reducing blood fat, the results show that the derivatives of the dihydrochalcone have the effects of obviously reducing serum total cholesterol and low-density lipoprotein cholesterol, and can be used to prepare medicines or health products for reducing blood fat, preventing and treating hyperlipoidemia, fatty liver, hepatocirrhosis and atherosclerosis and protecting the liver.

The invention belongs to the field of biotechnology, and relates to an experimental animal model for transforming nonalcoholic steatohepatitis into liver cancer. In particular, a large and mouse model of nonalcoholic chronic steatohepatitis (NASH) and chronic steatohepatitis developing into chronic liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) can be used for chronic fatty Liver, steatohepatitis, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, metabolic diseases, diabetes, in vivo experiments of related mechanisms of diabetic complications, new drug development, and non-alcoholic steatohepatitis (NASH), liver It has extremely high application value in the study of the pathogenesis of fibrosis and liver cancer and in drug development.

A Chinese medicine in the form of orally taken solid or liquid for treating viral hepatitis, chemical liver injury, fatty liver and hepatocirrhosis is prepared from 7 Chinese-medicinal materials including phylianthus urinaria, astragalus root, white atractylodes rhizome, notoginseng, etc.

The invention relates to an amphipathic compound of curcumin derivates and polyoxyethylene as well as a preparation method thereof, wherein PEO is polyoxyethylene, and R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 which are independently selected from hydrogen atom, hydroxide radical, phenyl, linear chain or branched chain alkyl group, linear chain or branched chain alkoxy, amidogen, mono-alkylation amidogen, dialkyl amine amidogen, halogen and halogenate alkyl group. The compound has the advantages of good compound stability, good water-solubility, good biocompatibility, low toxic and side effects, high bioavailability, low production cost and the like, and is easy to inject and administrate and the preparation process is simple. In addition, the invention also relates to an application ofthe amphipathic compound of curcumin derivates and polyoxyethylene in preparing the medicaments for resisting fatty liver, hepatic fibrosis and cirrhosis. The amphipathic compound has obvious pharmacology activity of resisting inflammation and hepatic fibrosis, delaying the forming of cirrhosis and reducing blood fat.

The invention relates to a medicament for treating acute and chronic hepatitis and process for preparation, wherein the medicament is prepared from silibinin-N-methylglucamine as the main constituent, and right mxtrix through a predetermined processing combinations. Compared with the existing dosage forms, the drop pill preparation has the advantages of short technological process, low cost of production and quick-effectiveness.

The invention relates to use of hepatocyte nuclear factor-1alpha in treatment of liver disease, particularly to use of hepatocyte nuclear factor-1alpha (HNF1alpha) in treatment of liver fibrosis and cirrhosis. The study of the invention shows that regulation of the expression of HNF1alpha gene can effectively generate an induction effect on the hepatocyte nuclear factor, so as to provide a new means of treatment.

The invention relates to a kind of the lecithin milky beverage. It contains (Wt.% per ton): fresh milk 200-400kg, sugar 40-60kg, asparteme 0.8-1.2kg, dairy stabilizer 4-6kg, citric acid monohydration 2-4kg, llactic acid 1-2Kg,sodium citrate 0.1-0.5Kg,lecithin 0.5-1.5Kg,milk flavor 0.1-0.4Kg,Citrus garadis flavor 0.2-0.4Kg,grapefruit flavor 0.1-0.3Kg,Garcinia mangostana L. flavor 0.1-0.3Kg,remaining water. Such product has the merit both of the nutrition from the milk and the lecithin function. It mainly works on dissolving the cholesterin,antiatherogenic;activation of the cells;activation of the brain enginery,prevention of the senile dementia;being young and long live, protecting your liver function. Alcohol and high cholesterin are two mainly factors to hepar adiposum and hepatocirrhosis, on the contrary, the lecithin can restore the damaged liver cells.

The invention relates to the field of non-invasive measurement, discloses a cirrhotic portal hypertension non-invasive evaluation method based on a 3D multi-channel convolutional neural network, and solves the problems that in the prior art, an invasive measurement method is high in risk, high in cost and high in operation difficulty, and the accuracy of a current clinical non-invasive predictionmodel is still affected by various interference factors. The method comprises the following steps: S1, acquiring a CTA layer sequence image of a patient with liver cirrhosis and portal hypertension ina portal period; S2, preprocessing the CTA layer sequence image; S3, performing segmentation based on the preprocessed CTA layer sequence image to obtain three-dimensional images of the liver, the spleen and the portal vein system; S4, extracting the characteristics of the three-dimensional images of the liver, spleen and portal system by adopting a multi-channel 3D convolutional neural network,and training by taking a measured HVPG grading value of the patient with liver cirrhosis portal hypertension as output to obtain a stable portal hypertension prediction model; and S5, evaluating the portal pressure of the patient through the stable portal high-pressure prediction model.

An application of the redback christmashush root in preparing the medicines for treating chronic hepatitis and hepatocirrhosis is disclosed.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The invention relates to the technical field of biology and discloses a non-alcoholic chronic fatty liver hepatitis (NASH) rat model and an establishment method and application thereof. An adult rat is fed with special feed (MCD feed) short of methionine and choline or a special high-fat feed (CDAA feed) short of choline, a certain amount of sodium nitrite solution is provided for the animal within a certain time, and the established non-alcoholic chronic fatty liver hepatitis rat model has the characteristics of chronic liver fibrosis and earlier liver fibrosis. The rat model is simple in establishment process, a technical means is easy, the establishment cost is low, the rat model has very high animal model value for scientific research and research and development of drugs, especially serves as a specific animal model with NASH accompanied with severe liver hepatitis and earlier liver fibrosis and belongs to a national initiative.

The invention discloses an efficient amplifying and culturing method for biliary epithelial cells in rabbit livers and belongs to the technical field of biological medicines. The efficient amplifying and culturing method comprises the following steps of: (1) separating, purifying and culturing the epithelial cells; (2) detecting cell growth lines; and (3) identifying the epithelial cells. The efficient amplifying and culturing method for the biliary epithelial cells, disclosed by the invention, has the advantages as follows: through a multi-step separating method, biliary epithelial cells with higher purities are obtained and a long-time multiplication culturing system for the biliary epithelial cells is established; a fact that the multiplication of the biliary epithelial cells in the livers can be obviously promoted through an Rho kinase inhibitor Y-27632 is first found; and the efficient amplifying and culturing method for the biliary epithelial cells, disclosed by the invention, has the advantages of simpler operation and the like, is suitable for promotion and application and can provide a platform for researches on a plurality of disease mechanisms including biliary atresia, primary biliary cirrhosis and the like.

The invention discloses an anti-hepatofibrosis traditional Chinese medicament composition and a preparation method thereof. The anti-hepatofibrosis traditional Chinese medicament composition is prepared by the following raw materials: bear gall powder, red sage root, curcumin and milk veteh. The anti-hepatofibrosis traditional Chinese medicament composition prepared by the preparation method can be prepared into any commonly used oral administration preparation, has obvious effects on treating hepatofibrosis, hepatitis, fatty liver, hepatocirrhosis and the like and has obvious medicament functions for protecting the liver, reducing aminotransferase and inhibiting the fibrosis of stem cells.

The invention relates to a rat culture method for transforming nonalcoholic steatohepatitis into hepatocellular carcinoma and an application of the method. The method and the application thereof effectively solve the problem that stable, reliable and effective model rats are provided for transforming nonalcoholic steatohepatitis into hepatocellular carcinoma, and technical support is provided foranimal experiments and new drug development of pathogenesis and development mechanisms of NASH, liver fibrosis, liver cirrhosis and HCC. The method includes adaptively feeding adult SD male rats weighing 250-300 g for 1 week, feeding a high-fat CDAA feed, adding diethylnitrosamine into drinking water for induction, observing mental state and hair condition of the rats, measuring intake and drinking water, and measuring weight of the rats every week; and calculating from the first feeding of high-fat CDAA diet and the addition of DEN into drinking water, and continuously culturing and feeding for 4-16 weeks to obtain rats transformed from nonalcoholic steatohepatitis to hepatocellular carcinoma. The method is easy to operate, short in time, stable and effective, and provides modeling and technical support for the research and development of new drugs for treating the transformation from nonalcoholic steatohepatitis to hepatocellular carcinoma.